2. Mach F., Baigent C., Catapano A.L. et al; ESC Scientific Document Group. 2019 ESC/EASGuidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020; 41(1): 111–88. doi: 10.1093/eurheartj/ehz455*.

3. Baigent C., Blackwell L., Emberson J. et al.; Cholesterol Treatment Trialists' (CTT) Collaboration.Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from170000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–81.

4. http://grls.rosminzdrav.ru/ (date of access – 01.10.2020).

5. Baigent C., Landray M.J. , Reith C. et al.; SHARP Investigators. The effects of lowering LDLcholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heartand Renal Protection): a randomised placebo-controlled trial. Lancet. 2011; 377(9784): 2181–92.doi: 10.1016/S0140–6736(11)60739–3.

6. Pandor A., Ara R.M., Tumur I. et al. Ezetimibe monotherapy for cholesterol lowering in 2,722people: systematic review and meta-analysis of randomized controlled trials. J Intern Med. 2009;265(5): 568–80. doi: 10.1111/j.1365–2796.2008.02062.x.

7. Sabatine M.S., Giugliano R.P., Keech A.C. et al.; FOURIER Steering Committee and Investigators.Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18): 1713–22. doi: 10.1056/nejmoa1615664.

8. Giugliano R.P., Pedersen T.R., Park J.-G. et al.; FOURIER Investigators. Clinical efficacy andsafety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab:a prespecified secondary analysis of the FOURIER trial. Lancet. 2017; 390(10106): 1962–71. doi:10.1016/s0140–6736(17)32290–0.

9. Schwartz G.G., Steg P.G., Szarek M. et al.; ODYSSEY OUTCOMES Committees and Investigators.Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22): 2097–107. doi: 10.1056/NEJMoa1801174.